Compass Therapeutics, Inc.
CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, whiā¦ read more
Healthcare
Biotechnology
5 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.39
Price+3.46%
$0.08
1Y
Price
Market Cap
$430.410m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR-25.0%
5y CAGREarnings
-$68.173m
-2.5%
1y CAGR-17.8%
3y CAGR-15.4%
5y CAGREPS
-$0.43
-2.4%
1y CAGR-9.4%
3y CAGR-5.6%
5y CAGRBook Value
$186.473m
$205.170m
Assets$18.697m
Liabilities$9.791m
DebtDebt to Assets
4.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$53.293m
-8.4%
1y CAGR-9.4%
3y CAGR-11.7%
5y CAGRNo items found.
Press Releases
Statements and updates from the company